Pharmacogenomics, also known as pharmacogenetics, is a field of research dedicated to investigating how an individual's genetic makeup influences their response to medications. Because pharmacogenomic testing analyzes germline DNA, the results remain valid for life, making PGx a foundational resource for clinical decision-making across a patient's entire care journey.
This webinar, hosted by Sano CEO Dr. Patrick Short and featuring Dr. Dimitar Tonev, an expert in liver disease and hepatology, sheds light on the latest developments in liver disease – particularly metabolic dysfunction-associated steatohepatitis (MASH) – including significant changes and predictions for the future.
Keeping participants engaged in clinical research can be difficult. Here, we let the statistics tell the story:
Genetic data is at the heart of precision medicine. Understanding the influence of genetics on health has helped us to recognise risk factors for disease, predict how patients might respond to treatments, and develop targeted treatments. But how does this knowledge connect to phenotypic data – the expression of the interaction between genes and the environment?
DPharm 2023 has come to a close, and as we reflect on the sessions and insights shared, two themes clearly stood out this year: The participant experience and incentives for participants. In this blog, we’ll dive deeper into these central areas of discussion.
As COVID-19 continues to affect us all, it has become evident that our fight against the virus is not just about developing vaccines and therapeutics. Equally crucial is our ability to track the virus’s mutations and adaptations. Enter genomic sequencing – a technology that has taken centre stage in our ongoing battle against the pandemic. Here, we explore how genomic sequencing has been instrumental in tracking SARS-CoV-2 variants and its implications for future pandemics.
The success of any precision medicine program depends on the quality of the target it pursues. A well-validated genetic target shapes everything downstream: which patients are eligible, how trials are designed, and whether therapies reach the right populations. For clinical operations and development teams, understanding how genetic data informs target discovery is not an academic exercise. It is the foundation on which recruitment strategies, eligibility criteria, and enrollment feasibility are built.
Long COVID, affecting nearly 28% of COVID-19 survivors, is a multifaceted condition that extends well beyond its initial impact. Typical include fatigue, concentration difficulties, and shortness of breath – but researchers have identified more than 200 symptoms associated with long COVID. It remains a global health puzzle, but research is paving the way for a deeper understanding and improved treatments.
In the ever-evolving landscape of clinical trial recruitment, an omnichannel approach is becoming increasingly crucial to ensure a diverse and engaged participant pool. This approach involves the integration of various outreach methods to reach potential participants through traditional methods, digital channels, patient advocacy groups, patient databases, and more. Each of these approaches has its pros and cons, offering unique opportunities and challenges to recruit participants effectively. Understanding these benefits and disadvantages can help researchers put together a perfectly blended omnichannel approach.
When an individual undergoes genetic testing, they often expect to find definitive answers about their genes. However, around 20% of genetic tests identify variants of uncertain significance (VUS). These genetic variants leave researchers and patients with more questions than answers.